KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short-term Investments (2022 - 2025)

Castle Biosciences (CSTL) has disclosed Short-term Investments for 4 consecutive years, with $182.8 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 5.39% to $182.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $182.8 million through Dec 2025, up 5.39% year-over-year, with the annual reading at $182.8 million for FY2025, 5.39% up from the prior year.
  • Short-term Investments hit $182.8 million in Q4 2025 for Castle Biosciences, down from $202.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $202.0 million in Q3 2025 to a low of $117.2 million in Q1 2023.
  • Historically, Short-term Investments has averaged $160.7 million across 4 years, with a median of $164.9 million in 2024.
  • Biggest five-year swings in Short-term Investments: increased 5.08% in 2023 and later surged 34.35% in 2024.
  • Year by year, Short-term Investments stood at $135.7 million in 2022, then increased by 6.32% to $144.3 million in 2023, then rose by 20.22% to $173.4 million in 2024, then increased by 5.39% to $182.8 million in 2025.
  • Business Quant data shows Short-term Investments for CSTL at $182.8 million in Q4 2025, $202.0 million in Q3 2025, and $193.7 million in Q2 2025.